No profile data available.
Nautilus Biotechnology, Inc. (NAUT) is a healthcare company in the biological analysis equipment industry, based in Seattle, United States, with about 127 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$59.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $10,000. Its market capitalization was $285.93 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Nautilus Biotechnology reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $10,000.
$285.93 million as of October 9, 2026.
Listed companies of a similar size in the same industry (biological analysis equipment) include Standard BioTools Inc. (LAB), Alpha Teknova, Inc. (TKNO), Quantum-Si incorporated (QSI), Quanterix Corporation (QTRX).